

Inducible Nitric Oxide Synthase Expression Is Reduced in Cystic Fibrosis Murine and Human Airway Epithelial Cells

Thomas J. Kelley* and Mitchell L. Drumm**

*Department of Pediatrics and **Department of Genetics and Center for Human Genetics, Case Western Reserve University, 8th Floor BRB, 10900 Euclid Avenue, Cleveland, Ohio 44106-4948

Abstract

It has been reported that exhaled nitric oxide levels are reduced in cystic fibrosis (CF) patients. We have examined the inducible isoform of nitric oxide synthase (iNOS) in the airways by immunostaining and found that iNOS is constitutively expressed in the airway epithelia of non-CF mouse and human tissues but essentially absent in the epithelium of CF airways. We explored potential consequences of lost iNOS expression and found that iNOS inhibition significantly increases mouse nasal *trans*-epithelial potential difference, and hindered the ability of excised mouse lungs to prevent growth of *Pseudomonas aeruginosa*. The absence of continuous nitric oxide production in epithelial cells of CF airways may play a role in two CF-associated characteristics: hyperabsorption of sodium and susceptibility to bacterial infections. (*J. Clin. Invest.* 1998. 102:1200–1207.) Key words: guanylate cyclase • cGMP • ion transport • bactericidal

Introduction

Although much has been learned about the function and regulation of the cystic fibrosis transmembrane conductance regulator (CFTR)¹ since its identification in 1989 (1, 2), it is still unclear how a defect in *trans*-apical chloride transport leads to the variety of airway symptoms associated with cystic fibrosis (CF). The causes of two common CF-associated airway abnormalities, hyperabsorption of sodium and chronic bacterial infection, remain mysteries. A loss of CFTR function may initiate a change in epithelial signaling cascades that adversely affects the function of vital cellular processes.

A direct or close physical interaction between CFTR and the epithelial sodium channel (ENaC) has been proposed to explain CF-related sodium hyperabsorption (3, 4). Although

there is evidence for a physical interaction, these data do not explain all the phenomena associated with ENaC. For example, amiloride-sensitive sodium transport is stimulated by cAMP in renal distal tubules, even though these cells express both CFTR and ENaC (5, 6). An alternative possibility is that the loss of some cellular signal in CF airway epithelia that normally serves to down-regulate sodium absorption may play a role in initiating the increased rate of sodium absorption. The process may be then further increased by altered protein kinase A regulation. A candidate for this lost signaling mechanism is nitric oxide (NO). NO is a known cell signaling agent that acts through the activation of soluble guanylate cyclases (GC-S), thus stimulating the production of cGMP (7). The ability of cGMP to effectively downregulate amiloride-sensitive sodium absorption has been demonstrated in several systems (8, 9). A loss of NO production would result in a loss of GC-S-mediated production of cGMP and presumably cause an increase in the rate of amiloride-sensitive sodium absorption. This model is consistent with several recent observations that exhaled NO levels are reduced in patients with CF (10–13). Although studies report little to no difference in orally exhaled NO levels between controls and CF patients, nasal NO levels are significantly reduced. Studying orally exhaled air, Grasmann et al. found a significant reduction in NO levels in CF patients compared with nonsmoking controls, especially when ambient room NO was taken into account (10). This study also found a positive correlation between NO levels and forced vital capacity. Their data suggest that lower levels of exhaled NO are an indication of more severe lung disease. Although not every study found a decrease in NO from orally exhaled air in CF patients compared with nondisease controls, there was clearly a lack of increased NO levels that would be expected in an inflammatory disease. Patients studied with asthma, for example, clearly have increased NO levels in orally exhaled air, serving as an indirect marker of inflammation (11). It is not clear why a chronically inflamed airway as is seen in CF does not exhibit this increase in NO production. This lack of NO production in CF airways occurs during chronic *Pseudomonas aeruginosa* infection, despite the fact that bacterial lipopolysaccharide (LPS) has been shown to stimulate NO production from airway macrophages and epithelial cells (14, 15). The inability of bacterial endotoxin to induce NO production in CF airway cells and the reported bactericidal activity of NO would suggest that an alteration in the NO pathway could result in the loss of a first-line epithelial defense mechanism.

Various reports have demonstrated that the inducible nitric oxide synthase isoform (iNOS) is constitutively expressed in tracheal and nasal epithelial cells in both rats and humans as well as human bronchial cells. This basal expression of iNOS by epithelial cells is apparently not due to iNOS induction by environmental factors since airway macrophages do not chronically express iNOS (16–18). Most cells can express iNOS when challenged with LPS or a combination of LPS and cytokines, such as interleukin-1 and tumor necrosis factor. How-

Address correspondence to Mitchell L. Drumm, Department of Pediatrics, Case Western Reserve University, 8th Floor BRB, 10900 Euclid Avenue, Cleveland, Ohio 44106-4948. Phone: 216-368-6893; FAX: 216-368-4223; E-mail: mx34@po.cwru.edu

Received for publication 25 November 1997 and accepted in revised form 23 July 1998.

1. Abbreviations used in this paper: CFTR, cystic fibrosis transmembrane conductance regulator; ENaC, epithelial sodium channel; GC-S, soluble guanylate cyclase; iNOS, inducible nitric oxide synthase; LPS, lipopolysaccharide; NO, nitric oxide.

J. Clin. Invest.

© The American Society for Clinical Investigation, Inc.

0021-9738/98/09/1200/08 \$2.00

Volume 102, Number 6, September 1998, 1200–1207

<http://www.jci.org>

ever, murine ileal mucosal cells and rat kidney epithelial cells have also been reported to continuously express iNOS in the absence of any cytokines or endotoxins (19, 20). These previous reports demonstrate that iNOS can play a role as a constitutively expressed source of NO production.

Tonic expression implies that iNOS activity has some regulatory role in airway epithelial cells. These roles can range from bactericidal activity to the regulation of gene expression, cell differentiation, epithelial microcirculation, and ciliary beat frequency. In this paper, we explore the differences in iNOS expression in CF and non-CF airway epithelial cells using a murine model and explore the possible role tonic NO production could have in explaining the CF-associated symptoms of hyperabsorption of sodium and chronic bacterial infection.

Methods

Determination of NOS activity and nitrate/nitrite levels. NOS activity was determined by homogenizing whole murine trachea in 50 mM Tris, pH 7.5, 1 mM EDTA, 5 mM KCl, 2 mM MgCl₂, and 0.1% polyethylene glycol (8,000 mol wt) (buffer A). Homogenate was spun at 4°C at 14,000 rpm in a microfuge for 15 min. Supernatant was retained and protein concentration determined by protein assay according to the manufacturer's instructions (Dc; Bio-Rad, Melville, NY). Reactions contained 10–25 µg of protein, 10 µM FAD, 200 µM NADPH, 100 µM tetrahydrobiopterin, 100 µM L-arginine, and 1 mM DTT in a 50-µl reaction volume in buffer A. Reactions were incubated for 90 min at 37°C. After incubation, the whole mixture was assayed for nitrate/nitrite levels according to the manufacturer's instructions in the CalBiochem (La Jolla, CA) NO colorimetric assay kit. Values were compared with those obtained with a standard curve of varying nitrate concentrations and reported as µM of nitrate/h/mg of protein.

Ex vivo nitrate/nitrite levels were determined by preparing the tissue by perfusing the vasculature of the lung with Krebs's buffered Ringer's (KBR) containing (115 mM NaCl, 25 mM NaHCO₃, 5 mM KCl, 2.5 mM Na₂HPO₄, 1.8 mM CaCl₂, 1.0 mM MgSO₄) through the heart until the lung turned white. PE-50 tubing was placed into the trachea and tied with suture. The lung and trachea were excised and lavaged five times with 1 ml of KBR. After lavaging, 0.3 ml of either KBR or KBR containing 10 µg/ml LPS from *P. aeruginosa* was infused into the lung, the PE tubing was capped, and the lung was placed in KBR bubbled with 95% O₂/5% CO₂ at 37°C for 1 h. After incubation, the lung was relavaged with 0.5 ml of KBR and the recovered lavage fluid assayed as described above for nitrate/nitrite levels.

iNOS-specific immunostaining. Lung sections of cfr (-/-) and cfr (+/+, -) mice were the kind gift of Thomas Ferkol, M.D., Case Western Reserve University, Cleveland, OH. Nasal epithelium was excised from cfr (-/-), cfr (+/+), and NOS2 (-/-) mice, paraffin blocked, and sectioned. Sections were deparaffinized, solubilized in ice-cold methanol for 5 min, and placed in 2% goat immunoglobulin in PBS for 2 h. Antibody against mouse and human iNOS was obtained from CalBiochem and incubated with the samples at 4°C overnight at a dilution of 1:300 in PBS. Samples were washed four times in PBS for 10 min per wash. Goat anti-rabbit IgG conjugated to alkaline phosphatase was diluted 1:200 in PBS and incubated with samples for 2 h at 37°C. Samples were washed as before and stained for 20 min in Vector Red from Novacastra Laboratories Ltd. (Newcastle, UK) according to manufacturer's instructions, and slides were counter-stained with hematoxylin. Quantitation of staining was performed using ImagePro imaging software (Media Cybernetics, Silver Springs, MD).

Nasal trans-epithelial potential difference (TEPD) measurements. TEPD measurements were made as described previously (21, 22). Mice treated with the iNOS inhibitor S-methylisothiourea (SMT) had 25 µl of SMT (100 mM) placed dropwise on their nostrils and were allowed to inhale each drop. Each mouse received three treatments a

day ranging from 5–10 h between treatments for 2 d. Mice were assayed 1–2 h after the final treatment. Aminoguanidine-treated mice received a single intraperitoneal injection of aminoguanidine (150 mg/kg of body weight) and were assayed 1–1.5 h after injection.

Determination of bactericidal activity. Colony-forming units (CFUs) of the ampicillin-resistant laboratory strain of *P. aeruginosa* PAO1 or the clinical isolate strain of *P. aeruginosa* PA M57-15 added to each experiment was determined by growing the bacteria overnight in Luria broth (LB) and diluting until the desired density was obtained. Various aliquots were plated on LB-agar plates in triplicate and incubated overnight at 37°C and counted. For in vitro bacterial killing with sodium nitroprusside (SNP), 5 µl of 1 × 10⁵ CFU/ml was added to a 20-µl reaction volume with various concentrations of SNP in HBR (10 mM Hepes, pH 7.4, 138 mM NaCl, 5 mM KCl, 2.5 mM Na₂HPO₄, 1.8 mM CaCl₂, 1.0 mM MgSO₄). Reactions were diluted in HBR, plated on LB-agar plates in duplicate, incubated at 37°C overnight, and counted. For assays of bactericidal activity in excised mouse lung, 1,500–2,000 CFU/ml bacteria were used. Lungs were prepared as described above, and 300 µl of diluted bacteria was placed in the lung and incubated for 1 h at 37°C. Lavage fluid was plated in triplicate, incubated overnight, and counted. Experiments using PAO1 *P. aeruginosa* were plated on LB-agar plates containing ampicillin (100 µg/ml).

Mice. Mice were genotyped from tail-clip DNA. ΔF508 mice were a generous gift from Kirk Thomas from the University of Utah School of Medicine (Salt Lake City, UT) and were genotyped by the procedures described previously (23). CFTR (-/-) (24) and NOS2 (-/-) (25) mice were obtained from Jackson Laboratories (Bar Harbor, ME), and cfr (-/-) were genotyped as described by Koller et al. (26). To increase survival of CF animals, mice were fed a liquid diet as described by Eckman et al. (27). Mice were cared for in accordance with Case Western Reserve University IACUC guidelines.

Results

Expression and activity of airway iNOS in wild-type and CF mice. The ability of wt mice and mice homozygous for the ΔF508 CFTR (cfr (ΔF508/ΔF508)) mutation to produce NO in response to LPS challenge was tested by measuring the levels of nitrate/nitrite in lavage fluid of excised lungs. Nitrate in the samples was further reduced to nitrite as described in Methods, and samples were compared with a standard curve of varying nitrate concentrations; therefore, results are given as micromolar nitrate. Lavage fluid from the excised lungs of mice expressing wt CFTR in the absence of LPS contained 5.7 ± 1.6 µM nitrate (*n* = 3), whereas lungs treated for 1 h at 37°C with LPS (10 µg/ml) were found to have levels of 27.1 ± 7.6 µM nitrate (*n* = 4) (Fig. 1 A). The LPS-mediated increase in NO production appears to be iNOS-dependent. Co-incubation with the iNOS-specific inhibitor SMT (100 µM) prevented LPS-mediated increases in NO production, reducing recovered nitrate values to 4.3 ± 2.6 µM nitrate (*n* = 3). Lungs excised from cfr (ΔF508/ΔF508) mice failed to respond similarly to LPS. Lavage fluid from untreated cfr (ΔF508/ΔF508) mouse lungs contained 2.4 ± 1.6 µM nitrate (*n* = 3) compared with 2.0 ± 1.0 µM nitrate (*n* = 3) in LPS-treated lungs. Similar results are observed when the NOS substrate L-arginine is incubated with excised lung. The addition of L-arginine (100 µM) in excised lungs from cfr (+/+, ΔF508) increases nitrate values to 42.2 ± 10.0 µM (*n* = 5), whereas lungs from cfr (ΔF508, ΔF508) only generate 6.4 ± 6.2 µM nitrate (*n* = 2) in response to L-arginine.

To determine if there is a quantitative difference in NOS activity in mouse airways, total NOS activity was measured




Figure 1. Airway NOS activity. (A) Nitrate/nitrite levels recovered from the excised lungs of wt (cfr (+/+,ΔF508)) and ΔF508 (cfr (ΔF508/ΔF508)) mice in the presence of either LPS (10 μg/ml), L-arginine (100 μM), or LPS + SMT (100 μM). CFTR (+/+,ΔF508) refers to both wild type homozygous and ΔF508 heterozygous animals. *Values significantly higher ($P < 0.01$) than wt control; **values significantly lower ($P < 0.05$) than wt control. P values determined by Duncan's multiple range test. Number of experiments for each condition is given in parentheses. (B) NOS-specific activities of whole trachea homogenates from cfr (-/-) mice and nonsibling heterozygous controls, as well as from cfr (ΔF508/ΔF508) mice and age-matched heterozygous siblings. *Values significantly greater ($P < 0.05$) than those obtained from homozygous mice as determined by t test. Number of experiments for each group is given in parentheses. Error bars represent SEM.

from whole trachea taken from both CF and non-CF mice. Mice carrying mutations that prevent CFTR expression [cfr (-/-) mice] were found to have a specific activity of 67.1 ± 42.1 μM nitrate/h/mg of protein ($n = 4$) compared with 255 ± 57.5 μM nitrate/h/mg of protein ($n = 3$) in nonsibling non-CF mice (Fig. 1 B). A similar difference was found comparing NOS activity in trachea from cfr (ΔF508/ΔF508) mice and age-matched siblings. Total NOS activity from cfr (ΔF508/ΔF508) mice was found to be 13.3 ± 6.7 μM nitrate/h/mg of protein ($n = 3$) compared with 311.3 ± 86.2 μM nitrate/h/mg of protein ($n = 3$) from siblings, suggesting that total NO production is reduced in the airways of mice carrying CF mutations.

iNOS is reported to be continuously expressed in the airway epithelium of humans, suggesting that this isoform is largely responsible for the production of NO in airways (18). Immunohistochemistry using a polyclonal antibody against iNOS was used to test directly for iNOS expression in lung sections taken from cfr (-/-) and cfr (+/+, -) mice and in sections of human trachea from CF and non-CF subjects. As shown in Fig. 2, the airway epithelium from a normal mouse shows high expression of iNOS compared with the epithelium of a cfr (-/-) mouse, consistent with the above data showing reduced NO production in CF mice. To address the question of specificity of the iNOS antibody, nasal epithelia were excised and sectioned from cfr (-/-) and cfr (+/+) mice, as well as mice that lack the expression of the inducible form of NOS [NOS2 (-/-)] as a control (Fig. 3). Immunostaining of nasal epithelial sections from the NOS2 (-/-) mouse reveals no detectable expression of iNOS protein and no detectable cross-reactivity with either endothelial NOS or neuronal NOS, both of which are reportedly normally expressed in the NOS2 (-/-) mice (27). Nasal epithelium was chosen for these stud-




Figure 2. iNOS-specific immunostaining in sections from CF and non-CF mouse lung and CF and non-CF human trachea. A, C, E, and G show sections of cfr (-/-) mouse lung, cfr (+/-) mouse lung, CF human trachea, and a non-CF human trachea, respectively. B, D, F, and H show fluorescence through a rhodamine filter of anti-iNOS IgG binding in corresponding fields.

ies to compare iNOS expression in upper respiratory epithelial cells with expression in the lower airways. Since the lack of iNOS expression is maintained in CF nasal epithelial cells, the effects of a lack of iNOS expression on various ion transport parameters can be examined. Also consistent with previous reports, there is high expression of iNOS in the epithelium of non-CF human trachea. The human CF tracheal tissue, however, shows very little iNOS staining in the epithelium, supporting previous findings that exhaled nasal NO levels are reduced in patients with CF (13). These mice have not been infected or exposed to exogenous cytokines or endotoxins, suggesting that iNOS is continuously expressed in non-CF murine epithelium as is seen in human airway epithelium.

Effect of decreased NO production on amiloride-sensitive sodium absorption. NO is an effective activator of GC-S, and cGMP is a known regulator of amiloride-sensitive sodium ab-




Figure 3. iNOS-specific immunostaining in sections from cftr (+/+), cftr (-/-), and NOS2 (-/-) mouse nasal epithelium. *A*, *B*, and *C* show bright field views of sections from cftr (+/+), cftr (-/-), and NOS2 (-/-) mouse nasal epithelium, respectively. *D*, *E*, and *F* show fluorescence through a rhodamine filter of anti-iNOS IgG binding in corresponding fields.

sorption (9). To assess a possible role of decreased iNOS expression in the CF-related characteristic of sodium hyperabsorption, the effects of the NO donor SNP on tracheal cGMP production and on nasal TEPD were tested.

Using excised whole trachea, cftr ($\Delta F508/\Delta F508$) mice responded approximately sevenfold more to SNP than non-CF mice in their ability to produce cGMP in the presence of NO (Fig. 4 *A*). Levels of cGMP increased from 443.7 ± 173.2 fmol of cGMP/mg of protein ($n = 5$) in untreated cftr (+/+, $\Delta F508$) mice to 665.0 ± 143.8 fmol of cGMP/mg of protein ($n = 5$) in mice treated with SNP (100 μM). However, cftr ($\Delta F508/\Delta F508$) mice showed increases from 427.2 ± 125.7 fmol of cGMP/mg of protein ($n = 3$) in untreated trachea to 4605.6 ± 1951.3 fmol of cGMP/mg of protein ($n = 3$) in SNP-treated trachea. These data show that CF airways appear to be hypersensitive to exogenous NO addition, possibly due to an upregulation of NO-sensitive guanylate cyclase in the absence of tonic NO production by the epithelium. Despite a clearly altered reaction to exogenously added NO, basal levels of cGMP in CF and non-CF mouse trachea appear to be very similar. This finding may be due to the fact that whole tracheas were used as opposed to isolated epithelial cells, and cGMP levels from other cell types are being detected in the basal measurement. Similarly, there may be high turnover of cGMP produced through NO-dependent guanylate cyclases since our hypothesis would suggest that this pool of cGMP would be important in regulating a sensitive ion transport process, thus not contributing significantly to total cGMP content.

If increased NO does reduce airway epithelial sodium absorption, the above findings predict that exogenously added SNP will reduce nasal TEPD in mice carrying CFTR muta-




Figure 4. Differential effects of NO in cftr (+/+, $\Delta F508$) and cftr ($\Delta F508/\Delta F508$) airways. (*A*) Production of cGMP stimulated by the addition of the NO donor SNP in excised whole tracheas. Number of experiments for each group is given in parentheses. Error bars represent SEM. $*P = 0.002$ as determined by Duncan's multiple range test compared with cftr (+/+, $\Delta F508$) control group. (*B*) Change in nasal TEPD stimulated by the addition of SNP in cftr (+/+, $\Delta F508$) and cftr ($\Delta F508/\Delta F508$) mice. Average baseline TEPD values were 9.0 ± 0.9 mV and 29.8 ± 1.6 mV for cftr (+/+, $\Delta F508$) and cftr ($\Delta F508/\Delta F508$) mice, respectively. $*P = 0.002$ as determined by *t* test.

tions. Comparing age-matched mice from the same colony, cftr (+/+, $\Delta F508$) mice showed a 1.9 ± 0.3 mV ($n = 4$) depolarization of nasal TEPD in the presence of SNP (100 μM), while SNP induced a 5.5 ± 0.5 mV ($n = 3$) depolarization of nasal TEPD in cftr ($\Delta F508/\Delta F508$) mice (Fig. 4 *B*).

The differences in TEPD and sodium absorption characteristic of CF airways should be mimicked by the inhibition of NOS activity if NO plays an important role in the tonic regulation of ion transport. Using the iNOS-selective inhibitor SMT, which we have previously shown to inhibit LPS-induced NO production in excised mouse lung, we examined its effects on amiloride- and SNP-sensitive sodium absorption in mouse nasal epithelia. Nasal TEPD values before treatment with SMT for cftr (+/+, -) mice averaged -8.3 ± 0.6 mV ($n = 7$). Mice were treated by placing 25 μl of a high concentration of SMT (100 mM) over the nostrils and letting the mice inhale the solution through the nasal cavity. After three treatments over a 2-d period with SMT, baseline TEPD increased to -14.9 ± 0.8 mV ($n = 7$, $P = 0.0005$) (Fig. 5). 3 d after the last SMT exposure, baseline TEPD values of tested mice returned to -8.2 ± 1.6 mV ($n = 3$) (data not shown). This experiment was also performed in a blinded fashion, where either Ringer's or SMT (100 mM) was administered to the mice and nasal TEPD measurements were performed blinded. Mice treated with Ringer's had baseline nasal TEPD values of -6.1 ± 0.8 mV and -6.6 ± 1.1 mV before and after treatment, respectively. Mice treated with SMT, however, showed an increase of baseline nasal TEPD values from -8.0 ± 1.0 mV to -16.0 ± 1.7 mV (data not shown; $n = 4$, $P = 0.02$). Depolarization of TEPD induced by amiloride (100 μM) increased in magnitude from 3.0 ± 0.4 mV before treatment to 5.1 ± 0.4 mV ($n = 4$) after SMT treatment, although the percentage change was not significantly altered. Due to a slow, continued depolarization of TEPD in the presence of amiloride, stable plateau values were not consistently reached. Therefore, the above values were taken 2 min after the addition of amiloride and likely underestimate the contributions of amiloride-sensitive sodium absorption to TEPD. To confirm that these changes were due to iNOS inhibition, a second iNOS-selective inhibitor was tested. Aminoguanidine (150 mg/kg of body weight) was injected in-




Figure 5. Effect of iNOS inhibition on baseline TEPD in cfr (+/+, -) mice. *A* and *B* show raw traces of a wt mouse (*A*) before and (*B*) after treatment with SMT. Solid bar shows the presence of amiloride. *C* shows cfr (+/+, -) mice before and after treatment with SMT, and *D* shows the magnitude of the depolarization of lumen negative TEPD due to amiloride. Changes in amiloride were measured at 4 min, and plateau values were not always reached. *E* shows control mice injected with vehicle (PBS), while *F* shows baseline TEPD values of mice before and after receiving intraperitoneally injected aminoguanidine. Error bars represent SEM. * $P < 0.05$ as determined by *t* test.

traperitoneally approximately 1–1.5 h prior to nasal TEPD assay (24). Nasal TEPD values increased from -7.1 ± 1.4 mV prior to treatment to -11.7 ± 2.4 mV ($n = 9$) within 1.5 h after injection (Fig. 5, *E–F*). Mice injected with PBS, which was used as the vehicle, showed no change in TEPD. These data suggest that iNOS regulates baseline TEPD by reducing *trans*-epithelial sodium absorption.

The product of iNOS, NO, is known to stimulate the production of cGMP through the activation of NO-sensitive GC-S. To determine if NO is capable of regulating sodium absorption through this pathway, we used the GC-S-specific inhibitor ODQ and looked at its effects on *trans*-epithelial sodium absorption. Perfusing the nasal epithelium of cfr (+/+, -) mice with ODQ resulted in a hyperpolarization of TEPD from -6.9 ± 0.6 mV to -11.8 ± 1.8 mV ($n = 5$) within 3 min after the start of perfusion (Fig. 6). Pretreatment with either amiloride or the cGMP analog 8-Br-cGMP prevented ODQ-mediated hyperpolarization of TEPD, suggesting that NO influences amiloride-sensitive sodium absorption through cGMP production.




Figure 6. The effects of GC-S inhibition on mouse nasal TEPD in cfr (+/+, -) mice. The effect of the GC-S inhibitor ODQ (100 μ M) on mouse nasal TEPD without pretreatment (\square) or in the presence of either amiloride (100 μ M) (\bullet) or 8-Br-cGMP (100 μ M) (\blacktriangle). The presence of ODQ is shown by the open bar. Number of experiments for each group is given in parentheses. Error bars represent SEM.

NO as an epithelial defense mechanism against bacterial infections. Previous reports demonstrate that NO is an effective bactericidal agent (28–31). We show that the NO donor, SNP, is capable of killing bacteria in a concentration-dependent manner. SNP concentrations ranging from 10^{-7} to 10^{-3} M were used to look at bactericidal activity of NO with the *P. aeruginosa* strain PAO1 (Fig. 7). Significant decreases in bacterial recovery were achieved with 750 nM SNP, with subsequently higher concentrations of SNP having more pronounced bactericidal activity when a limited number of bacteria (~ 500 CFU) were used. When larger amounts of PAO1 were used ($> 10,000$ CFU), millimolar amounts of SNP were needed to kill bacteria (data not shown). Bactericidal activity was due to NO production rather than nonspecific toxicity of SNP, since the NO scavenger *N*-methyl-D-glucamine dithiocarbamate effectively prevented SNP-mediated killing of PAO1 (Fig. 7*B*).

NO has also been shown to be a significant mediator of murine resistance to airway infection by *P. aeruginosa* (31). Injection of the normally infection-resistant BALB/c mice with the NOS inhibitor aminoguanidine severely decreased their ability to control the growth of *P. aeruginosa*. Aminoguanidine had no effect, however, on the infection-susceptible DBA/2 mice, suggesting that reduced NO production in the DBA/2 mice is a factor in their increased susceptibility to *P. aeruginosa* infection. Since our earlier experiments had shown that excised lungs from cfr ($\Delta F508/\Delta F508$) mice were deficient in their ability to produce NO in response to LPS compared with wt mice, the ability of excised lungs from these groups of mice to kill bacteria were compared. In all bactericidal experiments, a KBR solution containing 115 mM NaCl and 5 mM KCl was used to eliminate bacterial killing by salt-sensitive antibacterial




Figure 7. Bactericidal activity of NO. (A) PAO1 bacteria (424 ± 69 cfu/reaction) were incubated with various concentrations of the NO donor SNP. The solid line connects the mean %cfu recovered for each concentration. $*P = 0.0001$ and $**P < 0.00005$ as determined by Duncan's multiple range test compared to CFU recovered in the absence of SNP. Each point represents an individual reaction. (B) PAO1 ($> 10,000$ CFU) was streaked on a plate and bacterial growth was tested in the presence of (1) Hepes-buffered Ringer's (HBR), (2) 50 mM SNP, (3) 50 mM SNP + 50 mM MGD (a NO scavenger), and (4) 50 mM MGD.

peptides (32, 33). Adding approximately 500 CFU of either PAO1 or the clinical isolate PA M57-15 to each lung, only 68 ± 20 CFU ($n = 9$) were recovered from the lungs of wt mice (Fig. 8). However, 994 ± 208 CFU of PAO1 were recovered from cfr ($\Delta F508/\Delta F508$) mice ($n = 3$). The iNOS inhibitor, SMT, is capable of eliminating the ability of wt mice to produce NO in response to LPS, mimicking the result found with the cfr ($\Delta F508/\Delta F508$) mice and their inability to produce NO in response to LPS. The bactericidal activity apparently endogenous to wt mouse lung was tested in the presence of SMT to determine if iNOS has a potential role in antibacterial epithelial defense mechanisms. Using both PAO1 and the clinical isolate of *P. aeruginosa*, PA M57-15, bactericidal activity in excised lungs was tested in the presence of SMT. Again with ~ 500 CFU of either PAO1 or PA M57-15 added to each excised lung, an average of 400 ± 69 CFU ($n = 7$) were recovered from SMT-treated lungs. Excised lungs challenged with a low level inoculum of bacteria were used to approximate initial bacterial challenge to an airway lumen and to avoid artifacts of cultured epithelial cells. The contributions of luminal macrophages were minimized by removal through lavage. How NO affects more chronic, in vivo bacterial challenges in murine airways remains to be determined. These data suggest that en-




Figure 8. Comparison of *P. aeruginosa* killing in excised lungs of cfr ($+/+, \Delta F508$) and cfr ($\Delta F508/\Delta F508$) mice. PAO1 (\bullet) and a clinical isolate PA M57-15 (\circ) were tested in cfr ($+/+, \Delta F508$) in the presence and absence of the iNOS inhibitor SMT. An average of 541 ± 32 CFU of *P. aeruginosa* were used for each assay. Solid bars indicate average CFU recovered and error bars represent SEM. Each point shows an individual experiment. $*P < 0.05$ as determined by *t* test compared with CFU recovered from cfr ($+/+, \Delta F508$) in the absence of SMT.

dogenously produced NO may have a role in preventing the initiation of bacterial infections in the airways.

Discussion

Exhaled air from CF patients has been shown to contain decreased amounts of NO despite chronic bacterial infection and inflammation (10). This finding is inconsistent with other inflammatory airway diseases, such as asthma where exhaled NO levels are significantly increased (11, 31–37). Possible explanations for this discrepancy are that either poorly cleared mucous prevents the highly reactive NO from reaching air spaces to be expelled or that bacterial NO reductase activity eliminates NO produced in the airways. Based on evidence that iNOS is a constitutively expressed isoform in airway epithelial cells, we examined whether iNOS expression and function were reduced in CF airways using both cfr ($-/-$) and cfr ($\Delta F508/\Delta F508$) mice as model systems. We found that total NOS-specific activity was greatly reduced in the trachea of CF mice compared with wt controls and that excised mouse lungs from CF mice fail to produce NO in response to LPS challenge or to the NOS substrate L-arginine. These data establish that there is a functional difference in the ability of airways of CF mice to produce NO compared with wt controls. Also, immunostains specific for the iNOS isoform in both human tracheal and murine lung sections clearly show that iNOS is constitutively expressed in airway epithelial cells of non-CF airways and nearly absent in the epithelium of CF airways. These data

are consistent with other reports that show iNOS expression in airway epithelial cells from various sources and offer a possible explanation for the lack of exhaled NO in CF patients. By analogy, these observations suggest that reduced expired NO from CF patients may not be a direct consequence of infection or inflammation, but rather a reduction in iNOS expression resulting from reduced CFTR function.

We have also explored possible consequences of chronic loss of iNOS expression in airway epithelial cells. An initial consequence is that trachea from CF mice appear to be hypersensitive to exogenously added NO when measured by induced cGMP production. Non-CF mice increased cGMP levels only 1.5-fold in the presence of the NO donor SNP, while trachea from CF mice showed a 10.8-fold increase. Our data indicate that this phenomenon may not be observable in cultured airway cells. We have seen that even non-CF airway cells placed in culture fail to produce iNOS and exhibit increased production of cGMP in response to SNP (data not shown). This observation is consistent with a previous report that demonstrates airway epithelial cells cultured *ex vivo* lose their iNOS expression (12). The lack of iNOS expression in cultured cells would help explain apparent differences in cGMP production in response to SNP previously shown in non-CF airway epithelial cells. Human airway cells placed in primary culture show equal response to both C-type natriuretic peptide and SNP in stimulated production of cGMP (38). Our own report shows that Calu-3 cells produce significant amounts of cGMP in response to SNP (39). We have found neither iNOS activity nor expression associated with our cultures of Calu-3 cells (data not shown). A possible explanation for this effect is that NO-sensitive elements such as GC-S are upregulated in the absence of constitutive NO production. The mechanisms behind these differences will need to be explored in greater detail.

Amiloride-sensitive sodium absorption is known to be regulated by cGMP in several systems. A lack of NO production would theoretically reduce GC-S-mediated cGMP production and result in the loss of a negative-regulatory effector of sodium absorption. This mechanism would offer a possible explanation for the poorly understood CF characteristic of hyperabsorption of sodium across airway epithelium. We have shown increased sodium absorption in response to iNOS inhibition using two different inhibitors, SMT and aminoguanidine. We have also shown that inhibition of the NO-sensitive GC-S with the inhibitor ODQ results in hyperpolarization of nasal epithelia, directly implicating NO-induced cGMP as a tonic regulator of sodium transport. The NO donor SNP also produced a greater magnitude of epithelial depolarization both in *cftr* ($\Delta F508/\Delta F508$) mice and SMT-treated wt mice compared with untreated wt mice. It is likely that other factors contribute to increased sodium transport in CF airways such as atypical PKA regulation of ENaC (3) or abnormal ion gradients due to a lack of CFTR function. Other sodium transport mechanisms are known to be regulated by NO. Both Na^+/K^+ -ATPase and Na^+/H^+ exchanger have been shown to be inhibited by NO-dependent mechanisms in porcine cerebral cortex and rabbit proximal tubule, respectively, although the exact mechanisms of inhibition are not well understood (40, 41). NO has also been reported to stimulate Na^+/K^+ -ATPase human corpus cavernosum smooth muscle, further complicating the understanding of this regulatory process (42). These reports, coupled with those that describe NO and cGMP regulation of

amiloride-sensitive sodium absorption in vascular and intestinal tissues, demonstrate that NO is a potent paracrine or autocrine regulator of sodium transport through a variety of mechanisms. Although more study is needed, a loss of NO production resulting in the loss of subsequent signaling cascades represents a potential mechanism for initiating the process of sodium hyperabsorption in CF airways.

Another possible consequence of decreased iNOS expression and activity would be a loss of an initial defense mechanism against bacterial infection. Bactericidal activity has been associated with NO and its production is stimulated by bacterial endotoxins and cytokines. Losing the ability to express the iNOS isoform in particular would hinder the ability of the epithelium to defend itself against bacterial challenge. We have demonstrated that airways of *cftr* ($\Delta F508/\Delta F508$) mice are diminished in their ability to clear strains of *P. aeruginosa*. Non-CF mice, however, are capable of bactericidal activity even in a high-salt Ringer's, which should eliminate contributions of salt-sensitive defensin peptides (32). The antibacterial activity of non-CF airways was significantly reduced by the presence of the iNOS-specific inhibitor SMT, mimicking the inability of the *cftr* ($\Delta F508/\Delta F508$) lungs to kill PAO1 bacteria. It is likely that other processes, such as the production of bactericidal peptides (32, 33), play significant roles in airway antibacterial mechanisms. A dramatic reduction of iNOS expression and function throughout the airway epithelium, however, would severely hinder an important first-line defense mechanism and would increase the susceptibility of the airways to bacterial infections.

We have established that murine CF airway epithelium is lacking in both total NO production and in iNOS expression. Although this paper has focused on iNOS expression due to its role in immunological responses, the function and expression of both endothelial NOS and neuronal NOS will need to be explored in the future, as well as what other cell types, such as macrophages, may also exhibit this change in iNOS expression. We have also shown that the possible consequences of reduced iNOS activity in airway epithelium correlate directly to two of the least well characterized aspects of CF: sodium hyperabsorption and chronic bacterial infection. These findings suggest that NO therapy may be beneficial to CF patients and they open a new area in which to look for other related therapeutic options. Determining the mechanism of how a loss of CFTR function leads to reduced iNOS expression will likely be a key to understanding cell signaling changes that occur in CF and hopefully lead to more effective therapeutic interventions.

Note added in proof: Subsequent to our submission of this work, Meng et al. (Meng, Q., D.R. Springall, A.E. Bishop, K. Morgan, T.J. Evans, S. Habib, D.C. Gruentert, K.M. Gyi, M.E. Hodson, M.H. Yacoub, and J.M. Polak. 1998. Lack of inducible nitric oxide synthase in bronchial epithelium: a possible mechanism of susceptibility to infection in cystic fibrosis. *J. Pathol.* 184:323–331) have published that iNOS expression is reduced in CF patients and in CF cell lines, complementing the studies and supporting the results presented here.

Acknowledgments

This work was supported by National Institutes of Health grants HL-50160 and DK-51878 and by a grant from the Cystic Fibrosis Foundation.

References

1. Rommens, J.M., M.C. Iannuzzi, B. Kerem, M.L. Drumm, G. Melmer, M. Dean, R. Rozmahel, J.L. Cole, D. Kennedy, N. Hidaka, et al. 1989. Identification of the cystic fibrosis gene: chromosome walking and jumping. *Science*. 245: 1059–1065.
2. Riordan, J.R., J.M. Rommens, B. Kerem, N. Alon, R. Rozmahel, Z. Grzelczak, J. Zielenski, S. Lok, N. Plavsic, J.L. Chou, et al. 1989. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. *Science*. 245:1066–1073.
3. Stutts, M.J., C.M. Canessa, J.C. Olsen, M. Hamrick, J.A. Cohn, B.C. Rossier, and R.C. Boucher. 1995. CFTR as a cAMP-dependent regulator of sodium channels. *Science*. 269:847–850.
4. Ismailov, I.I., M.S. Awayda, B. Jovov, B.K. Berdiev, C.M. Fuller, J.R. Dedman, M.A. Kaetzel, and B.A. Benos. 1996. Regulation of epithelial sodium channel by the cystic fibrosis transmembrane conductance regulator. *J. Biol. Chem.* 271:4725–4732.
5. Costanzo, L.S., and E.E. Windhager. 1980. Effects of PTH, ADH, and cyclic AMP on distal tubular Ca and Na reabsorption. *Am. J. Physiol.* 239:F478–F485.
6. Crawford, I., P.C. Maloney, P.L. Zeitlin, W.B. Guggino, S.C. Hyde, H. Turley, K.C. Gatter, A. Harris, and C.F. Higgins. 1991. Immunocytochemical localization of the cystic fibrosis gene product CFTR. *Proc. Natl. Acad. Sci. USA*. 88:9262–9266.
7. Moncada, S., R.M.J. Palmer, and E.A. Higgs. 1991. Nitric oxide: physiology, pathophysiology and pharmacology. *Pharmacol. Rev.* 43:109–142.
8. Light, D.B., E.M. Schwiebert, K.H. Karlson, and B.A. Stanton. 1989. Atrial natriuretic peptide inhibits a cation channel in renal inner medullary collecting duct cells. *Science*. 243:383–385.
9. Rozenweig, A., and C.E. Seidman. 1991. Atrial natriuretic factor and related peptide hormones. *Annu. Rev. Biochem.* 60:1463–1464.
10. Grasemann, H., E. Michler, M. Wallot, and F. Ratjen. 1997. Decreased concentration of exhaled nitric oxide (NO) in patients with cystic fibrosis. *Pediatr. Pulmonol.* 24:173–177.
11. Lundberg, J.O., S.L. Nordvall, E. Weitzberg, H. Kollberg, and K. Alving. 1996. Exhaled nitric oxide in paediatric asthma and cystic fibrosis. *Arch. Dis. Childhood*. 75:323–326.
12. Balfour-Lynn, I.M., A. Laverly, and R. Dinwiddie. 1996. Reduced upper airway nitric oxide in cystic fibrosis. *Arch. Dis. Childhood*. 75:319–322.
13. Dotsch, J., S. Demirakca, H.G. Terbrack, G. Hulls, W. Rascher, and P.G. Kuhl. 1996. Airway nitric oxide in asthmatic children and patients with cystic fibrosis. *Eur. Resp. J.* 9:2537–2540.
14. Hibbs, J.B., R.R. Taintor, Z. Vavrin, and E.M. Rachlin. 1988. Nitric oxide: a cytotoxic activated macrophage effector molecule. *Biochem. Biophys. Res. Commun.* 157:87–94.
15. Pheng, L.H., C. Francoeur, and M. Denis. 1995. The involvement of nitric oxide in a mouse model of adult respiratory distress syndrome. *Inflammation*. 19:599–610.
16. Felley-Bosco, E., S. Ambs, C.J. Lowenstein, L.K. Keefer, and C.C. Harris. 1994. Constitutive expression of inducible nitric oxide synthase in human bronchial epithelial cells induces c-fos and stimulates the cGMP pathway. *Am. J. Resp. Cell Mol. Biol.* 11:159–164.
17. Rosbe, K.W., J.W. Mims, J. Prazma, P. Petrusz, A. Rose, and A.F. Drake. 1996. Immunohistochemical localization of nitric oxide synthase activity in upper respiratory epithelium. *Laryngoscope*. 106:1075–1079.
18. Guo, F.H., H.R. DeRaeve, T.W. Rice, D.J. Stuehr, F.B.J.M. Thunnissen, and S.C. Erzurum. 1995. Continuous nitric oxide synthesis by inducible nitric oxide synthase in normal human airway epithelium in vivo. *Proc. Natl. Acad. Sci. USA*. 92:7809–7813.
19. Ahn, K.Y., M.G. Mohaupt, K.M. Madsen, and B.C. Kone. 1994. In situ hybridization localization of mRNA encoding inducible nitric oxide synthase in rat kidney. *Am. J. Physiol.* 267:F748–F757.
20. Hoffman, R.A., G. Zhang, N. Nussler, S.L. Gleixner, H.R. Ford, R.L. Simmons, and S.C. Watkins. 1997. Constitutive expression of inducible nitric oxide synthase in the mouse ileal mucosal. *Am. J. Physiol.* 272:G383–G392.
21. Grubb, B.R., R.N. Vick, and R.C. Boucher. 1994. Hyperabsorption of Na⁺ and raised Ca(2⁺)-mediated Cl⁻ secretion in nasal epithelial of CF mice. *Am. J. Physiol.* 266:C1478–C1483.
22. Kelley, T.J., K. Thomas, L.J.H. Milgram, and M.L. Drumm. 1997. In vivo activation of the cystic fibrosis transmembrane conductance regulator mutant ΔF508 in murine nasal epithelium. *Proc. Natl. Acad. Sci. USA*. 94:2604–2608.
23. Zeiher, B.G., E. Eichwald, J. Zabner, J.J. Smith, A.P. Puga, P.B. McRay, M.R. Capecchi, M.J. Welsh, and K.R. Thomas. 1995. A mouse model for the ΔF508 allele of cystic fibrosis. *J. Clin. Invest.* 96:2051–2064.
24. Snouwaert, J.N., K.K. Brigman, A.M. Latour, N.N. Malouf, R.C. Boucher, O. Smithies, B.H. Koller. 1992. An animal model for cystic fibrosis made by gene targeting. *Science*. 257:1083–1088.
25. MacMicking, J.D., C. Nathan, G. Hom, N. Chartrain, D.S. Fletcher, M. Trumbauer, K. Stevens, Q.-W. Xie, K. Sokol, N. Hutchinson, et al. 1995. Altered response to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. *Cell*. 81:641–650.
26. Koller, B.H., H.S. Kim, A.M. Latour, K. Brigman, R.C. Boucher, P. Scambler, B. Wainwright, and O. Smithies. 1991. Toward an animal model of cystic fibrosis: targeted interruption of exon 10 of the cystic fibrosis transmembrane regulator gene in embryonic stem cells. *Proc. Natl. Acad. Sci. USA*. 88: 10730–10734.
27. Eckman, E., C.U. Cotton, D.M. Kube, and P.B. Davis. 1995. Dietary changes improve survival of CFTR S489X homozygous mutant mouse. *Am. J. Physiol.* 269:L625–L630.
28. Saito, S., K. Onozuka, H. Shinomiya, and M. Nakano. 1991. Sensitivity of bacteria to NaNO₂ and to L-arginine-dependent system in murine macrophages. *Microbiol. Immunol.* 35:325–329.
29. Ottaviani, E., L.R. Paemen, P. Cadet, and G.B. Stefano. 1993. Evidence for nitric oxide production and utilization as a bactericidal agent by invertebrate immunocytes. *Eur. J. Pharmacol.* 248:319–324.
30. Schmidt, H.H.H.W., and U. Walter. 1994. NO at work. *Cell*. 78:919–925.
31. Gosselin, D., J. DeSanctis, M. Boule, E. Skamene, C. Matouk, and D. Radzioch. 1995. Role of tumor necrosis factor alpha in innate resistance to mouse pulmonary infection with *Pseudomonas aeruginosa*. *Infect. Immun.* 63: 3272–3278.
32. Smith, J.J., S.M. Travis, E.P. Greenberg, and M.J. Welsh. 1996. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. *Cell*. 85:229–236.
33. Goldman, M.J., G.M. Anderson, E.D. Stolzenberg, U.P. Kari, M. Zasloff, and J.M. Wilson. 1997. Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. *Cell*. 86:553–560.
34. Barnes, P.J. 1993. Nitric oxide and airways. *Eur. Resp. J.* 6:163–165.
35. Persson, M.G., O. Zetterstrom, V. Agrenius, E. Ihre, and L.E. Gustafsson. 1993. Single-breath nitric oxide measurements in asthmatic patients and smokers. *Lancet*. 343:146–147.
36. Hamid, Q., D.R. Springall, V. Riveros-Moreno, P. Chanez, P. Howarth, A. Redington, J. Bousquet, P. Godard, S. Holgate, and J.M. Polak. 1993. Induction of nitric oxide synthase in asthma. *Lancet*. 342:1510–1513.
37. Kharitonov, S.A., D. Yates, R.A. Robbins, R. Logan-Sinclair, E.A. Shinebourne, and P.J. Barnes. 1994. Increased nitric oxide in exhaled air of asthmatic patients. *Lancet*. 343:133–135.
38. Geary, C.A., M.F. Goy, and R. Boucher. 1993. Synthesis and vectorial export of cGMP in airway epithelium: expression of soluble and CNP-specific guanylate cyclases. *Am. J. Physiol.* 263:L598–L605.
39. Kelley, T.J., L. Al-Nakkash, and M.L. Drumm. 1997. C-type natriuretic peptide control of chloride secretion in airway epithelial cells. *Am. J. Resp. Cell Mol. Biol.* 16:464–470.
40. Sato, T., Y. Kamata, M. Irifune, and T. Nishikawa. 1995. Inhibition of purified (Na⁺, K⁺)-ATPase activity from porcine cerebral cortex by NO generating drugs. *Brain Res.* 704:177–120.
41. Roczniak, A., and K.D. Burns. 1996. Nitric oxide stimulates guanylate cyclase and regulates sodium transport in rabbit proximal tubule. *Am. J. Physiol.* 270:F106–F115.
42. Gupta, S., R.B. Moreland, R. Munarriz, J. Daley, I. Goldstein, and I.S. de Tejada. *Br. J. Pharm.* 116:2201–2206.